Stockhub

Oscotec Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

22 September 2022

  • curprev 05:1405:14, 22 September 2022 95.149.241.133 talk 1,078 bytes +1,078 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Ph..."
Retrieved from "https://stockhub.co/research/Oscotec_Inc."